Neuronetics revises Q4 2024 results: net loss up to $12.7M from $12.2M on Greenbrook acquisition accounting adjustments

Neuronetics, Inc.

Q4 2024 net loss revised to $(12.7)M ($(0.34)/share) from $(12.2)M ($(0.33)/share) initially reported.
Q4 adjusted EBITDA now $(0.4)M, down from $0.1M reported on March 4, 2025.
Full-year 2024 net loss revised to $(43.7)M ($(1.38)/share) from $(43.2)M ($(1.37)/share).
Full-year adjusted EBITDA revised to $(21.8)M from $(21.3)M previously.
Revision caused by $0.6M reduction in assumed Greenbrook bonus accrual under purchase accounting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.